GlassScriptPhysician profile
Chandra Adhikari
NPI 1912754078
$4,160.09
in general payments reported to CMS, 2019-2025
22 companies · $2,853 in 2025
The $2,853 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,307 · 2025: $2,853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,160.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,139.07 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $365.65 | 2024-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $364.60 | 2024-2025 | Xifaxan |
| Madrigal Pharmaceuticals | $335.33 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $303.18 | 2024-2025 | |
| Genzyme Corporation | $244.33 | 2024-2025 | |
| Janssen Biotech, INC. | $216.88 | 2024-2025 | Tremfya, Stelara |
| Regeneron Healthcare Solutions, INC. | $211.69 | 2024-2025 | Dupixent |
| Ardelyx, INC. | $165.42 | 2024-2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $141.86 | 2024-2025 | Iqirvo, Bylvay |
| Lilly USA, LLC | $133.14 | 2024-2025 | Omvoh |
| Qol Medical, LLC | $122.81 | 2024-2025 | Sucraid, Sucraid |
| Ethicon US, LLC | $112.64 | 2025 | Harmonic, Linx Reflux Management System |
| Gilead Sciences, INC. | $93.21 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $71.79 | 2025 | Zenpep, Vowst |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $29.98 | 2025 | Vegzelma |
| Novo Nordisk INC | $26.58 | 2025 | Wegovy |
| Celgene Corporation | $20.64 | 2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $16.83 | 2024 | |
| Alnylam Pharmaceuticals INC. | $15.49 | 2024 | Givlaari |
| Vivus LLC | $15.46 | 2025 | Pancreaze |
| Intercept Pharmaceuticals, INC. | $13.51 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chandra Adhikari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.